Review
Oncology
Masmudur M. Rahman, Grant McFadden
Summary: Oncolytic viruses (OVs) are a novel cancer treatment modality that selectively target and kill cancer cells while sparing normal ones. Engineered OVs show great potential in clinical trials, but combination therapies with other treatments may further improve their efficacy.
Article
Pharmacology & Pharmacy
Seyed-Mahmood Seyed-Khorrami, Arezou Azadi, Nasrin Rastegarvand, Ala Habibian, Hoorieh Soleimanjahi, Marek J. Los
Summary: Immunotherapy and virotherapy have emerged as new methods for cancer treatment, with better specificity and outcomes. Applying these strategies in the treatment of malignancies is of great significance, based on advances in understanding cancer cell biology and oncolytic viruses.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Review
Medical Laboratory Technology
Noraini Abd-Aziz, Chit Laa Poh
Summary: Oncolytic virotherapy is a therapeutic approach that utilizes replication-competent viruses to selectively kill cancer cells, but it faces limitations such as viral delivery, tumor penetration, and antiviral immune responses. Strategies to overcome these limitations are crucial for its effective application in preclinical and clinical trials.
TRANSLATIONAL RESEARCH
(2021)
Review
Oncology
Mobarakeh Ajam-Hosseini, Fatemeh Akhoondi, Mohammad Doroudian
Summary: Oncolytic viruses show promise as a dual attack therapy for cancer, but their effectiveness is hindered by elimination in the body. Nanoparticles have the potential for targeted drug delivery, but face challenges in non-specificity. By encapsulating oncolytic viruses with nanoparticles, the efficacy of both treatments can be improved and successful clinical results have been achieved. In this review, we will discuss the mechanisms and benefits of each treatment method.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Shengye Jin, Qin Wang, Hao Wu, Da Pang, Shouping Xu
Summary: Biological therapy, particularly oncolytic viruses (OVs), has shown promising therapeutic effects in various cancers, including triple negative breast cancer (TNBC). TNBC, lacking conventional treatment targets, benefits from the emerging concept of OVs for potential treatment options.
BIOMARKER RESEARCH
(2021)
Review
Virology
Alexander Malogolovkin, Nizami Gasanov, Alexander Egorov, Marianna Weener, Roman Ivanov, Alexander Karabelsky
Summary: Recent breakthroughs in cancer immunotherapy have transformed oncology and provided new hope for a cure. The combination of oncolytic viruses with immune checkpoint inhibitors shows promise, but finding the most effective combinations remains complex. This review highlights the efficacy, safety, and future perspectives of virotherapy based on clinical trial data.
Review
Oncology
Arash Letafati, Omid Salahi Ardekani, Mina Naderisemiromi, Mohammad Mehdi Fazeli, Nillofar Asadi Jemezghani, Jila Yavarian
Summary: Cancer treatment is a challenging field in medical sciences, with different approaches yielding limited success. Virus-based treatments offer a potential alternative to chemotherapy, with fewer side effects and promising outcomes.
Review
Oncology
Michael L. Monaco, Omer A. Idris, Karim Essani
Summary: Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer and lacks available molecular-based therapeutics. Recurrence and tumor heterogeneity pose challenges to treatment approaches. Immuno-oncolytic viruses (OVs) have shown promise in treating TNBC, and this review summarizes their strategies and testing stages.
Review
Medicine, General & Internal
Henglong Hu, Qidong Xia, Jia Hu, Shaogang Wang
Summary: Bladder cancer is a common type of cancer and oncolytic viruses hold great promise as an immunotherapeutic strategy for its treatment. Various oncolytic viruses have been studied in preclinical and clinical research, and this review provides an overview of the advances in oncolytic viruses for bladder cancer treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Nasser Hashemi Goradel, Arezoo Alizadeh, Shahnaz Hosseinzadeh, Mitra Taghipour, Zeinab Ghesmati, Arash Arashkia, Babak Negahdari
Summary: Oncolytic virotherapy has emerged as a powerful therapeutic approach in cancer treatment, showing promising results in killing tumor cells and boosting immune responses. However, resistance to oncolytic viruses remains the main challenge, with various mechanisms and strategies being studied to overcome this barrier.
Review
Biochemistry & Molecular Biology
Camille Robinson, Maria M. Xu, Smita K. Nair, Georgia M. Beasley, Kristen E. Rhodin
Summary: Malignant melanoma recurrence can present in various ways, requiring personalized management. Oncolytic viruses can stimulate local immune response and potentially overcome anti-PD-1 therapy resistance. Currently, one oncolytic virus is FDA-approved for this population, with other viruses under investigation.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Review
Oncology
Bart Spiesschaert, Katharina Angerer, John Park, Guido Wollmann
Summary: Combinations of oncolytic viruses with specific small molecule compounds can help overcome limitations in their ability to replicate and kill tumors in clinical settings. This review focuses on mechanisms by which small molecules can synergize with oncolytic viruses to enhance viral replication, tumor cell killing, and antitumor immune responses.
Review
Biotechnology & Applied Microbiology
Yang Gao, Yan Wu, Tian Huan, Xiaoyan Wang, Jun Xu, Qinggang Xu, Feng Yu, Haifeng Shi
Summary: Oncolytic therapy modifies virus genes to combat tumor cells, showing progress in clinical studies through biomolecular technology advancements to enhance efficacy.
BIOTECHNOLOGY LETTERS
(2021)
Review
Oncology
Jyoti Malhotra, Edward S. Kim
Summary: This review summarizes the recent trials and current status of oncolytic viruses (OVs) for the treatment of lung cancer. While early-phase trials have shown evidence of antiviral immune responses and clinical benefit, the clinical efficacy of OVs in larger trials has not been confirmed. The development of novel combinations with OVs, along with improving tumor specificity and viral load, may be crucial for improving the efficacy of OVs in lung cancer treatment.
CURRENT ONCOLOGY REPORTS
(2023)
Review
Oncology
Charlotte Lovatt, Alan L. Parker
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their efficacy is limited to patients with significant lymphocyte infiltration. Oncolytic viruses (OVs) have shown promise in selectively killing tumor cells and inducing immunogenic cell death, making them a potential modality for combination therapy to overcome the limitations of ICIs. By increasing immune cell infiltration and inducing anti-tumor immunity, OVs can change the cold tumor microenvironment associated with poor response to ICIs, rendering patients more susceptible to these therapies.